Free Trial

Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.5% in October

Immunic logo with Medical background

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 3,470,000 shares, an increase of 29.5% from the September 30th total of 2,680,000 shares. Based on an average daily volume of 576,100 shares, the days-to-cover ratio is currently 6.0 days.

Institutional Trading of Immunic

Institutional investors and hedge funds have recently bought and sold shares of the business. BVF Inc. IL bought a new position in shares of Immunic during the first quarter worth approximately $11,752,000. Janus Henderson Group PLC bought a new position in shares of Immunic during the first quarter worth approximately $9,266,000. Vanguard Group Inc. increased its stake in shares of Immunic by 100.7% during the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company's stock worth $4,480,000 after purchasing an additional 1,703,047 shares during the period. Ikarian Capital LLC increased its stake in shares of Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company's stock worth $2,128,000 after purchasing an additional 1,162,378 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Immunic during the first quarter worth approximately $25,000. Institutional investors own 51.82% of the company's stock.

Immunic Price Performance

IMUX stock traded down $0.05 during trading hours on Monday, reaching $1.34. The stock had a trading volume of 889,817 shares, compared to its average volume of 594,656. The stock has a 50-day simple moving average of $1.52 and a 200 day simple moving average of $1.36. The stock has a market capitalization of $120.71 million, a PE ratio of -0.93 and a beta of 1.84. Immunic has a fifty-two week low of $0.95 and a fifty-two week high of $2.11.

Immunic (NASDAQ:IMUX - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.02. During the same period in the prior year, the business posted ($0.54) earnings per share. On average, sell-side analysts forecast that Immunic will post -0.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Leerink Partners reiterated an "outperform" rating and issued a $5.00 price target on shares of Immunic in a report on Monday, September 9th. StockNews.com upgraded shares of Immunic from a "sell" rating to a "hold" rating in a report on Tuesday, August 13th. Leerink Partnrs upgraded shares of Immunic to a "strong-buy" rating in a report on Monday, September 9th. EF Hutton Acquisition Co. I upgraded shares of Immunic to a "strong-buy" rating in a report on Monday, September 16th. Finally, B. Riley assumed coverage on shares of Immunic in a report on Tuesday, August 27th. They issued a "buy" rating and a $6.00 price target for the company. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $11.20.

Read Our Latest Analysis on Immunic

About Immunic

(Get Free Report)

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Further Reading

Should you invest $1,000 in Immunic right now?

Before you consider Immunic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.

While Immunic currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines